



Q4 2022 Financial Review

February 2023



DISCLAIMER



This presentation has been prepared by Ceragon Networks Ltd. ("Ceragon" or the "Company") for informational purposes only. This presentation and the information contained herein are proprietary to the Company and may not be reproduced (in whole or in part) nor summarized, used, distributed, disseminated and/or copied without the prior written consent by the Company.

Ceragon Networks® and FibeAir® are registered trademarks of Ceragon in the United States and other countries. CERAGON® is a trademark of Ceragon Networks Ltd., registered in various countries. Other names mentioned are owned by their respective holders.

Neither this presentation nor any of the information contained herein constitute an offer to sell or the solicitation of an offer to buy any securities. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. No offering of securities shall be made in Israel except pursuant to an effective prospectus under the Israeli Securities Law, 1968 or an exemption from the prospectus requirements under such law. This presentation does not constitute a proposal and/or an offer and/or invitation to acquire and/or to be issued shares or any other securities by the Company and/or to engage in any transaction. This presentation has been prepared to provide summary information to its recipients, but it does not, however, purport to present all material information regarding the Company and/or the subject matter thereof, and it is subject to, and must be read in conjunction with, all other publicly available information, including Ceragon's public filings with the Securities and Exchange Commission ("SEC"). In particular, the Company makes no representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein. Historical facts and past operating results are not intended to mean that future performances or results for any period will necessarily match or exceed those of any prior year.

Forward Looking Statements.

This presentation contains statements that constitute "forward-looking statements" within the meaning of the Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Ceragon's management about Ceragon's business, financial condition, results of operations, micro and macro market trends and other issues addressed or reflected therein. Examples of forward-looking statements include, but are not limited to, statements regarding: projections of demand, revenues, net income, gross margin, capital expenditures and liquidity, competitive pressures, order timing, supply chain and shipping, components availability, growth prospects, product development, financial resources, cost savings and other financial and market matters. You may identify these and other forward-looking statements by the use of words such as "may", "plans", "anticipates", "estimates", "targets", "expects", "intends", "potential" or the negative of such terms, or other comparable terminology, although not all forward-looking statements contain these identifying words.

Although we believe that the projections reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations therefrom will not be material. Such forward-looking statements involve known and unknown risks and unknown reasonable assumptions, we can give no assurance that our expectations will be obtained or the risk of penaltics and other commodities, on our unknown and unknown risks and unknown risks and the results of penaltics and orders cancellation created thereby, as well as profit erosion due to constant price increase in shipping costs and decrease in shipping costs and decr

We caution you not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Ceragon does not assume any obligation to update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release unless required by law.

Ceragon's public filings are available on the Securities and Exchange Commission's website at www.sec.gov and may also be obtained from Ceragon's website at www.sec.gov and may also be obtained from Ceragon's website at www.sec.gov and may also be obtained from Ceragon's website at www.sec.gov and may also be obtained from Ceragon's website at www.sec.gov and may also be obtained from Ceragon's website at www.sec.gov and may also be obtained from Ceragon's website at www.sec.gov and may also be obtained from Ceragon's website at www.sec.gov and may also be obtained from Ceragon's website at www.sec.gov and may also be obtained from Ceragon's website at www.sec.gov and may also be obtained from Ceragon's website at www.sec.gov and may also be obtained from Ceragon's website at www.sec.gov and may also be obtained from Ceragon's website at www.sec.gov and websit


Industry Data.


This presentation contains estimates and information that is based on industry publications, reports and peer company public filings. This information involves a number of assumptions and limitations, and you are cautioned not to rely on or give undue weight to this information. The Company has not independently verified the accuracy or completeness of the data contained in these industry publications, reports or filings.

Revenues- Geographic Split



	Q4/19	Q1/20	Q2/20	Q3/20	Q4/20	Q1/21	Q2/21	Q3/21	Q4/21	Q1/22	Q2/22	Q3/22	Q4/22
Europe	15%	15%	21%	14%	19%	19%	18%	15%	14%	17%	15%	13%	13%
Africa	7%	6%	4%	14%	10%	9%	8%	6%	9%	8%	6%	5%	7%
North America	13%	13%	15%	14%	16%	17%	19%	14%	16%	19%	21%	27%	23%
India	16%	25%	22%	24%	23%	26%	27%	35%	30%	22%	31%	28%	29%
APAC	18%	21%	19%	20%	14%	14%	11%	9%	10%	14%	11%	10%	11%
Latin America	31%	20%	19%	14%	18%	15%	17%	21%	21%	20%	16%	17%	17%
Total	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%





NON-GAAP Profit & Loss



	Actual (Unaudited)												
	Q4/19	Q1/20	Q2/20	Q3/20	Q4/20	Q1/21	Q2/21	Q3/21	Q4/21	Q1/22	Q2/22	Q3/22	Q4/22
Revenues	71,256	55,871	62,427	70,581	74,002	68,270	68,621	76,115	77,760	70,319	70,674	78,649	75,531
Cost of Revenues	48,980	41,833	45,891	46,970	52,631	48,087	47,005	52,509	55,199	50,850	49,142	50,699	50,551
Gross profit	22,276	14,038	16,536	23,611	21,371	20,183	21,616	23,606	22,561	19,469	21,532	27,950	24,980
Gross margin	31.3%	25.1%	26.5%	33.5%	28.9%	29.6%	31.5%	31.0%	29.0%	27.7%	30.5%	35.5%	33.1%
Research & Development	7,558	7,201	6,760	7,299	7,694	7,358	7,494	6,640	7,745	6,779	7,493	7,150	7,863
% R&D	10.6%	12.9%	10.8%	10.3%	10.4%	10.8%	10.9%	8.7%	10.0%	9.6%	10.6%	9.1%	10.4%
Selling & Marketing	9,975	8,173	8,032	7,819	8,452	8,186	8,266	8,349	8,681	8,495	9,060	8,280	8,605
% S&M	14.0%	14.6%	12.9%	11.1%	11.4%	12.0%	12.0%	11.0%	11.2%	12.1%	12.8%	10.5%	11.4%
General & Administration	6,836	4,246	4,755	4,754	4,680	3,934	5,247	4,645	4,616	4,803	4,612	6,116	5,357
% G&A	9.6%	7.6%	7.6%	6.7%	6.3%	5.8%	7.6%	6.1%	5.9%	6.8%	6.5%	7.8%	7.1%
Total operating expenses	24,369	19,620	19,547	19,872	20,826	19,478	21,007	19,634	21,042	20,077	21,165	21,546	21,825
Operating profit (loss)	(2,093)	(5,582)	(3,011)	3,739	545	705	609	3,972	1,519	(608)	367	6,404	3,155
Operating margin	-2.9%	-10.0%	-4.8%	5.3%	0.7%	1.0%	0.9%	5.2%	2.0%	-0.9%	0.5%	8.1%	4.2%
Non-GAAP EBITDA	587	(2,878)	(331)	6,467	3,494	3,591	3,552	6,931	4,977	2,333	3,201	9,047	5,777
Financial expenses and													
others, net	(2,071)	(758)	(1,354)	(1,238)	(2,527)	(1,237)	(1,367)	(2,273)	(2,691)	(1,184)	(2,531)	(2,011)	(2,858)
Income Tax	(801)	(365)	(487)	(201)	(1,559)	(347)	(420)	(348)	(855)	(61)	(304)	(269)	(534)
Non GAAP Net income	(4,965)	(6,705)	(4,852)	2,300	(3,541)	(879)	(1,178)	1,351	(2,027)	(1,853)	(2,468)	4,124	(237)
Non GAAP EPS	(0.06)	(0.08)	(0.06)	0.03	(0.04)	(0.01)	(0.01)	0.02	(0.02)	(0.02)	(0.03)	0.05	(0.00)
# of Shares for diluted EPS													
('000)	80,575	80,765	81,013	82,244	81,536	82,584	83,424	85,271	83,916	83,959	84,019	85,970	84,348



Selected Cash Flow Data

(U.S. dollars in thousands)													
	Q4/19	Q1/20	Q2/20	Q3/20	Q4/20	Q1/21	Q2/21	Q3/21	Q4/21	Q1/22	Q2/22	Q3/22	Q4/22
Total cash & cash equivalents	23,939	44,120	35,167	29,155	27,101	33,011	28,670	27,235	17,079	24,960	23,592	25,964	22,948
Cash flow from operations	8,607	3,127	6,666	(3,225)	10,677	(1,654)	(2,958)	(667)	(9,740)	(1,816)	(3,173)	8,597	(8,503)
Capital expenditures	(2,627)	(1,202)	(2,715)	(1,230)	(1,342)	(2,003)	(1,728)	(2,336)	(3,328)	(2,726)	(3,079)	(4,487)	(2,129)
Options Exercise	211	246	308	293	390	3,689	269	730	42	81	32	297	-
Proceeds (repayment) of short-term bank credits and loans, net	(2,000)	10.055	(40.475)	(4.000)	(44.000)	5.000				12.150	4.050	(2, 222)	-
Other	(2,800)	18,255 (245)	(13,176)	(1,800)	(11,900) 121	6,000 (122)	76	900 (62)	2,900 (30)	12,150 192	4,950 (98)	(2,000) (35)	7,600 16
Net Change in Cash	3,415	20,181	(8,953)	(6,012)	(2,054)	5,910	(4,341)	(1,435)	(10,156)	7,881	(1,368)	2,372	(3,016)



Selected Balance Sheet Data

	(U.S. dollars in thousands)													
	Q4/19	Q1/20	Q2/20	Q3/20	Q4/20	Q1/21	Q2/21	Q3/21	Q4/21	Q1/22	Q2/22	Q3/22	Q4/22	
Cash and Cash Equivalents	23,939	44,120	35,167	29,155	27,101	33,011	28,670	27,235	17,079	24,960	23,592	25,964	22,948	
Trade Receivables	118,531	104,185	97,547	108,394	107,388	106,712	107,404	109,863	118,310	120,682	122,734	115,871	112,324	
DSOs	151	140	136	152	149	141	139	140	149	150	152	142	139	
Inventory	62,132	59,659	53,593	51,869	50,627	48,542	52,316	53,203	61,398	58,060	60,710	64,227	72,009	
Inventory Days	120	117	106	103	99	92	98	97	111	103	107	114	130	
Working capital	111,267	102,830	98,206	102,067	99,446	98,954	99,864	101,615	87,799	87,494	82,105	83,335	90,201	
Short-term loans	14,600	32,855	19,679	17,879	5,979	11,979	11,000	11,900	14,800	26,950	31,900	29,900	37,500	
Shareholders' Equity	160,421	151,414	147,329	149,662	146,126	146,397	146,310	147,663	137,151	135,856	131,973	132,757	132,073	
% - Shareholders' Equity/														
Total assets	55%	52%	54%	55%	54%	50%	50%	50%	47%	45%	43%	44%	44%	
Total Balance Sheet	289,889	292,671	272,097	273,759	272,419	291,098	294,416	295,416	292,563	300,187	304,980	302,336	301,608	

Reported results – Reconciliation to GAAP



(U.S. dollars in thousands)													
	Q4/19	Q1/20	Q2/20	Q3/20	Q4/20	Q1/21	Q2/21	Q3/21	Q4/21	Q1/22	Q2/22	Q3/22	Q4/22
Non GAAP Net income (loss)	(4,965)	(6,705)	(4,852)	2,300	(3,541)	(879)	(1,178)	1,351	(2,027)	(1,853)	(2,468)	4,124	(237)
Non GAAF Net Income (1033)	(4,903)	(0,703)	(4,652)	2,300	(3,341)	(873)	(1,170)	1,331	(2,027)	(1,655)	(2,400)	4,124	(237)
Stock based compensation													
expenses	459	426	441	384	411	351	286	1,034	891	746	689	1,167	958
Amortization of intangible													
assets	-	-	-	-	1,800	-	-	-	-	-	-	-	-
Changes in indirect tax	(0.64)	_			(2.22)				(200)		_	_	070
positions	(361)	1	1	1	(202)	1	2	2	(399)	-	1	1	279
Leases - financial expenses (income)	133	(450)	110	157	229	(186)	435	102	706	(425)	(1,774)	(233)	154
Paycheck protection	133	(430)	110	137	223	(100)	755	102	700	(423)	(1,777)	(233)	134
program	-	-	-	-	-	-	(979)	-	-	-	-	-	-
Retired CEO compensation	-	-	-	-	-	-	810	-	-	(96)	-	-	-
Hostile attempt related costs	-	-	-	-	-	-	-	-	-	-	-	3,971	249
Non-cash tax adjustments	(1,272)	15	(87)	76	2	128	(23)	(53)	8,987	210	136	81	851
Equity loss in affiliates	177	183	160	98	538	-	-	-	-	-	-	-	-
GAAP Net Income (Loss)	(4,101)	(6,880)	(5,477)	1,584	(6,319)	(1,173)	(1,709)	266	(12,212)	(2,288)	(1,520)	(863)	(2,728)
GAAP EPS	(0.05)	(0.09)	(0.07)	0.02	(0.08)	(0.01)	(0.02)	0.00	(0.15)	(0.03)	(0.02)	(0.01)	(0.03)
# of Shares for basic EPS													
('000)	80,575	80,765	81,013	81,278	81,536	82,584	83,424	83,717	83,916	83,959	84,019	84,200	84,348
('000)	80,575	80,765	81,013	82,000	81,536	82,584	83,424	84,637	83,916	83,959	84,019	84,200	84,348

Quarterly Revenues and Non-GAAP Net Income (Loss) CERAGON

